More Despite safety warnings, Eisai/Biogen Alzheimer’s medication approvals are anticipated.
With U.S. approval of Eisai's and Biogen's Alzheimer's drug Leqembi secured, Wall…
Midday stock market movers include Rivian, Levi Strauss, Biogen, First Solar, and others.
Alibaba — U.S. shares of the Chinese company added 8.8% in afternoon trading.…
The largest premarket movers include Alibaba, Biogen, Levi Strauss, and more
Levi Strauss— The apparel retailer fell 7.7% after slashing its profit outlook…
Biogen’s stockholders support With Susan Langer at the helm.
Biogen (BIIB.O) shareholders elected former company executive Susan Langer as a director on Monday,…
ISS supports Langer’s selection to succeed former Biogen director Denner.
Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen <BIIB.O>…
Sarissa’s Denner resigns from the Biogen board while the company looks for seats at Alkermes.
Activist investor Sarissa Capital may have cleared a stumbling block in its…
Biogen, Eisai According to a study, Leqembi’s annual cost to US Medicare might reach $5 billion.
Wide coverage of Alzheimer's drug Leqembi would raise future costs for the…
Drug from Biogen that treats a rare type of ALS receives fast approval from the FDA.
The Food and Drug Administration on Tuesday granted accelerated approval for Biogen’s drug tofersen,…
Biogen’s ALS medication is rejected by FDA advisors due to the disease’s rare and aggressive version.
The Food and Drug Administration’s independent panel of advisors on Wednesday declined…
Genentech is suing Biogen for royalties on the popular MS medication.
Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco…